Show simple item record

dc.contributor.authorMartin, Peter 1967-en
dc.description.abstractTen years ago, the rediscovery of the atypical antipsychotic drug clozapine represented a breakthrough for the treatment of schizophrenia. Clozapine, among several other actions, potently antagonises serotonin (5-HT)2 receptors, and thus, it has been suggested that a truly selective 5-HT2 receptor antagonist may exert antipsychotic efficacy on its own. However, ritanserin, a selective 5-HT2 receptor antagonist, appeared active mainly against the negative (and depressive) symptoms of schizophrenia, with less effect on the positive symptom cluster. Clozapine and ritanserin block all three 5-HT2 receptor subtypes, ie the 5-HT2A, 5-HT2B and 5-HT2C receptors; the relative contribution to the therapeutic effect of antagonism at each subtype is not well-known. To address this issue we studied M100907, the first highly selective and potent antagonist at 5-HT2A receptors, in a hypoglutamatergia rodent model of schizophrenia. Based on the prevailing hypothesis that a glutamatergic deficiency is involved in the pathophysiology of schizophrenia, mice or rats were rendered hypoglutamatergic by means of acute systemic injections of MK-801, an un-competitive antagonist of the glutamatergic NMDA receptor. We argue that the hyperlocomotion induced by MK-801 is related to positive symptoms/acute episodes of schizophrenia. Effects on spontaneous locomotion of drug-naive rodents were measured to detect non-specific interactions with locomotor activity. Postmortem brain tissue or perfusates from in vivo microdialysis were analysed for monoamine levels. M100907 potently abolished MK-801-induced hyperlocomotion with no or minor reductions of spontaneous locomotion. Although ritanserin and M100907 have equal in vitro and in vivo potencies as 5-HT2A receptor antagonists, ritanserin displayed a 100-fold lower potency with regard to inhibition of MK-801-induced hyperlocomotion. This enigma was resolved by experiments where ritanserin was found to markedly counteract M100907 s inhibitory effect on MK-801-treated hyperlocomotion. This effect of ritanserin was probably mediated by antagonism at 5-HT2B/C receptors since similar, albeit weaker, effects were obtained with the selective 5-HT2B/C receptor antagonist SB206553. Further, in rats, spontaneous locomotion was significantly enhanced by ritanserin, accompanied by elevations in 3-MT in the striatum and limbic regions. MK-801 increased brain serotonin metabolism in rats and mice, and the levels of cortical 5-HIAA in MK-801-treated mice were positively correlated to locomotor activity. However, neurochemically verified depletion of serotonin by means of pretreatment with the 5-HT synthesis inhibitor PCPA, did only reduce MK-801 induced hyperlocomotion slightly (on average 17 %). At the same time, the inhibitory effect of M100907 (as well as low doses of clozapine or olanzapine) on MK-801-induced hyperlocomotion was abolished by PCPA pretreatment; the effect of M100907 was reinstated by acute administration of the 5-HT precursor 5-HTP or the 5-HT2A/B/C receptor agonist DOI. Taken together, the data suggest that endogenous 5-HT exerts a dual action on psychotic-like behaviour, ie promotes locomotion through stimulation of 5-HT2A receptors, and reduces locomotion through stimulation of other 5-HT (possibly 5-HT2C) receptors. Further, the antipsychotic-like effect of 5-HT2A receptor antagonists is dependent on increased serotonergic tone. Possible implications for the treatment of schizophrenia are discussed.en
dc.title5-HT2 receptor antagonism and antipsychotic drugs; a behavioural and neurochemical study in a rodent hypoglutamatergia modelen
dc.type.svepDoctoral thesisen
dc.gup.originGöteborgs universitet/University of Gothenburgeng
dc.gup.departmentDepartment of Pharmacologyeng
dc.gup.departmentAvdelningen för farmakologiswe

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record